Altimmune, inc.ALT.US Overview
ALT Overall Performance
ALT AI Analysis & Strategy
ALT Recent Performance
1.63%
Altimmune, inc.
0.81%
Avg of Sector
-1.14%
S&P500
ALT PowerScanner
ALT Key Information
ALT Valuation Metrics
ALT Earnings Table
ALT Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.